amyotrophic lateral sclerosis

A computer rendering of neuronal inclusions in Huntington’s disease

Clinical challenges: NfL as an emerging biomarker in Huntington’s disease

Neurofilament light chain (NfL) shows promise as a biomarker for disease progression and prognosis in Huntington’s disease (HD), although clinical utility still lies ahead. Having better biomarkers is important, “even in a disease like HD that we know is monogenic, we know the causal mutation in the Huntington’s gene, and we can do predictive genetic …

Clinical challenges: NfL as an emerging biomarker in Huntington’s disease Read More »

mRNA

Bayer and Amgen Join $120 Million Funding for Startup to Expand Genetic Drug Delivery

ReCode Therapeutics was founded around new science that may enable the delivery of genetic drugs to various organs in the body, and the startup has encouraging data for its therapeutic candidates targeting the lungs. Now the biotech startup $120 million to show that it can deliver on the technology’s promise in other organs and cell …

Bayer and Amgen Join $120 Million Funding for Startup to Expand Genetic Drug Delivery Read More »

Novartis Selects Precision Bio to Bring In Vivo Gene Editing Drugs for Blood Disorders

Genetic drugs in development for blood disorders include various therapies made by taking a patient’s cells and processing them outside the body. Novartis is one of the companies testing this approach, but also sees benefits in treating these diseases with therapies that work in the patient. The pharmaceutical giant is turning to Precision BioSciences’ technology …

Novartis Selects Precision Bio to Bring In Vivo Gene Editing Drugs for Blood Disorders Read More »